Modulation of Monocyte Activation by Atorvastatin in HIV Infection

Exclusion Criteria

• •1. Concomitant use of fibric acid derivatives or other lipid lowering agents including patients on statins and Ezetimibe
• •2. Use of any anti-inflammatory drugs (OTC or prescription) on a daily basis
• •3. Pregnancy or breast feeding
• •4. Active drug use or alcohol abuse/dependence, which in the opinion of the investigators will interfere with the patient's ability to participate in the study
• •5. Allergy or hypersensitivity to statins or any of its components
• •6. History of myositis or rhabdomyolysis with use of any statins
• •7. Patients who are on concurrent immunomodulatory agents, including systemic corticosteroids will be ineligible for 3 months after completion of therapy with the immunomodulating agents
• •8. History of inflammatory muscle disease such as poly or dermatomyositis
• •9. Serious intercurrent illness requiring systemic treatment and/or hospitalization within 30 days of entry
• •10. Evidence of active opportunistic infections requiring treatment or neoplasms that require chemotherapy during the study period
• •11. Creatine phosphokinase elevations (CPK) greater than 3 times the upper limit of normal
• •12. Known active liver disease or AST/ALT greater than 2x the upper limit of normal
• •13. Renal insufficiency, indicated by serum creatinine 2 mg/dl
• •14. Absolute neutrophil count (ANC) 1000/mm3, hemoglobin \< 10.0 g/dL for males and \<9 g/dL for females, platelet count 100,000/mm